Accreditation/Credit Designation

ACCME Credits
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Reciprocity
Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at:

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Optimizing Use of T-Cell–Engaging Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy. Progress is being made in terms of increased understanding of disease pathophysiology as related to identification of new cytogenetic and molecular abnormalities, as well as development of novel targeted agents. The addition of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, novel bispecific immune therapies, and chimeric antigen receptor (CAR) T cells to the treatment landscape has resulted in improved clinical outcomes. These new developments have shifted clinical management from a 'one size fits all' approach to a more individualized treatment approach based on immunophenotypic, cytogenetic and molecular features.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the live satellite symposium “Optimizing Use of T-Cell Engaging Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia” held in September 2021. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with ALL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists who treat patients with ALL. Hematologists, medical oncologists, and health care professionals interested in the treatment of ALL are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe the biology of ALL in terms of biomarkers, testing strategies, and methods to stratify risk
  • Outline the role of measurable residual disease status in treatment decisions for patients with ALL with T-cell–engaging immunotherapy
  • Incorporate key findings from recent clinical trials concerning the use of T-cell–engaging immunotherapy treatment strategies for patients with ALL in the frontline and relapsed/refractory (R/R) settings

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 


Anthony Mato, MD, MSCE
Elias Jabbour, MD
Professor of Medicine, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Disclosures: Grant/Research Support: Amgen Inc.; Pfizer Inc.; Takeda Pharmaceutical Company; Adaptive Biotechnologies; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; AbbVie Inc.; Bristol Myers Squibb.


Claudio Cerchione, MD, PhD
Claudio Cerchione, MD, PhD
Director Medical Research Hematology Unit
Romagnolo Scientific Institute for the Study and Treatment of Cancer
Meldola, Italy

Disclosures: Claudio Cerchione, MD, PhD, has no relevant financial relationships with ineligible companies.

Hagop M. Kantarjian, MD
Hagop M. Kantarjian, MD
Professor of Medicine
Chair, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Disclosures: Grant/Research Support: AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi-Sankyo, ImmunoGen, Jazz, Pfizer, Sanofi.

José María Ribera, MD, PhD
José María Ribera, MD, PhD
Associate Professor of Medicine
Autonomous University of Barcelona
Director, Stem Cell Transplantation Unit
Head, Clinical Hematology Department, Catalan Institute of Oncology
Germans Trias University Hospital
Badalona, Spain

Disclosures: Grant/Research Support: Incyte, Pfizer; Consultant: Amgen, Novartis, Takeda, Pfizer

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By